gemtuzumab ozogamicin

(redirected from Gemtuzumab)

gemtuzumab ozogamicin

 [gem-too´zoo-mab″ o″zo-gah-mi´sin]
a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.

gemtuzumab ozogamicin

/gem·tu·zu·mab ozo·ga·mi·cin/ (gem-too´zoo-mab″ o″zo-kah-mi´sin) a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic.

gemtuzumab ozogamicin

[gemto̅o̅′zo̅o̅mab′ o′zo-gah-mi′sin]
a recombinant DNA-derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.
Mentioned in ?
References in periodicals archive ?
An overview of products like I-Labelled Tositumomab (Bexxar), Y-Labelled Ibritumomab (Zevalin), Alemtuzumab (Campath), AdotrastuzumabEmtansine (Kadcyla), Bacillus Calmette-Guerin (BCG), Bevacizumab (Avastin), BrentuximabVedotin (Adcetris), Cetuximab (Erbitux), Cervarix, DenileukinDiftitox (Ontak), Gardasil, Gemtuzumab (Mylotarg), Hepatitis B Vaccine, Interferon Alfa (IFN-alfa), Interleukin-2 (IL-2), Ipilimumab (Yervoy), Ofatumumab (Arzerra), Panitumumab (Vectibix), Pembrolizumab (Keytruda), Rituximab (Mabthera), Sargramostim (Leukine), Sipuleucel-T (Provenge) and Trastuzumab (Herceptin) is provided in this research.
Patients given the new type of "smart drug" called Gemtuzumab Ozogamicin (GO) as well as chemotherapy were 22% less likely to relapse and around 13% less likely to die from their disease.
The research team studied more than 1,000 patients who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin, which is also known as Mylotarg.
The addresses of the institutions of the authors of the paper titled "Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed/refractory acute myleoid leukemia" which was published in Turkish Journal of Hematology Volume:25 Issue:1 Pages 36-41 were printed wrong due to the wrong information given by the authors.
Cytotoxic agents implicated in the development of hepatic SOS include busulfan, a common conditioning agent used in HSCT, and gemtuzumab ozogamycin (Mylotarg[R], Wyeth Pharmaceuticals), an anti-CD33 monoclonal antibody.
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab riuxetan (Zevalin), panitumumab (Vectibix), tositu-momab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
The following are examples of monoclonal antibodies: alemtuzumab, gemtuzumab, ozogamicin, rituximab, trastuzumab (herceptin).
Gemtuzumab, a humanised antiCD33 MoAb, is approved by the FDA in patients over 60 years in whom standard chemotherapy for acute myeloblastic leukaemia (AML) has failed.
Tokyo, Japan, July 27, 2005 - (JCNN) - Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare.
9, 2013 /PRNewswire/ -- The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
The research team studied more than a thousand patients who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin, which is also known as Mylotarg.
MYLOTARG(R) (gemtuzumab ozogamicin) is contraindicated in patients with a known hypersensitivity to gemtuzumab ozogamicin or any of its components and in lactating mothers.